AU2020207265B2 - Multi-functional fusion proteins and uses thereof - Google Patents

Multi-functional fusion proteins and uses thereof

Info

Publication number
AU2020207265B2
AU2020207265B2 AU2020207265A AU2020207265A AU2020207265B2 AU 2020207265 B2 AU2020207265 B2 AU 2020207265B2 AU 2020207265 A AU2020207265 A AU 2020207265A AU 2020207265 A AU2020207265 A AU 2020207265A AU 2020207265 B2 AU2020207265 B2 AU 2020207265B2
Authority
AU
Australia
Prior art keywords
component
receptor
hfca
fcb
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020207265A
Other languages
English (en)
Other versions
AU2020207265A1 (en
Inventor
Carmella Romeo SMITH
Mark L. Tykocinski
Matthew C. WEBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of AU2020207265A1 publication Critical patent/AU2020207265A1/en
Application granted granted Critical
Publication of AU2020207265B2 publication Critical patent/AU2020207265B2/en
Priority to AU2026204884A priority Critical patent/AU2026204884A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020207265A 2019-01-07 2020-01-07 Multi-functional fusion proteins and uses thereof Active AU2020207265B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026204884A AU2026204884A1 (en) 2019-01-07 2026-06-23 Multi-functional fusion proteins and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789212P 2019-01-07 2019-01-07
US62/789,212 2019-01-07
PCT/US2020/012624 WO2020146423A1 (en) 2019-01-07 2020-01-07 Multi-functional fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026204884A Division AU2026204884A1 (en) 2019-01-07 2026-06-23 Multi-functional fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
AU2020207265A1 AU2020207265A1 (en) 2021-08-12
AU2020207265B2 true AU2020207265B2 (en) 2026-03-26

Family

ID=71521906

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020207265A Active AU2020207265B2 (en) 2019-01-07 2020-01-07 Multi-functional fusion proteins and uses thereof
AU2026204884A Pending AU2026204884A1 (en) 2019-01-07 2026-06-23 Multi-functional fusion proteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026204884A Pending AU2026204884A1 (en) 2019-01-07 2026-06-23 Multi-functional fusion proteins and uses thereof

Country Status (12)

Country Link
US (2) US12497439B2 (enExample)
EP (1) EP3908664A4 (enExample)
JP (1) JP7587505B2 (enExample)
KR (2) KR20260116815A (enExample)
CN (1) CN113518823B (enExample)
AU (2) AU2020207265B2 (enExample)
BR (1) BR112021013415A2 (enExample)
CA (1) CA3125748A1 (enExample)
IL (1) IL284679A (enExample)
MX (1) MX2021008207A (enExample)
SG (1) SG11202107454UA (enExample)
WO (1) WO2020146423A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
CN113518823B (zh) 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途
EP4175656A4 (en) * 2020-07-03 2024-10-16 The Trustees of Columbia University in the City of New York POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
WO2022188129A1 (zh) * 2021-03-12 2022-09-15 利时雨 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用
CN118369336A (zh) * 2022-04-15 2024-07-19 Im生技股份有限公司 具有改进半衰期的融合蛋白平台

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121085A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2018234793A2 (en) * 2017-06-20 2018-12-27 Kymab Limited ANTIBODY

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056591A1 (en) 2000-02-03 2001-08-09 Thomas Jefferson University vMIP-II PEPTIDE ANTAGONISTS OF CXCR4
US7897152B2 (en) * 2000-09-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-antigen fusion proteins
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
EP3030322A2 (en) 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CN109608544B (zh) * 2015-11-17 2022-09-16 苏州盛迪亚生物医药有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
JP6732915B2 (ja) * 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
WO2018209017A1 (en) * 2017-05-10 2018-11-15 The General Hospital Corporation Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor
RU2766590C2 (ru) * 2017-05-16 2022-03-15 Цзянсу Хэнжуй Медисин Ко., Лтд. Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
CN113518823B (zh) 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121085A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2018234793A2 (en) * 2017-06-20 2018-12-27 Kymab Limited ANTIBODY

Also Published As

Publication number Publication date
CN113518823A (zh) 2021-10-19
JP2022528030A (ja) 2022-06-08
CA3125748A1 (en) 2020-07-16
EP3908664A4 (en) 2023-01-25
US20220056102A1 (en) 2022-02-24
BR112021013415A2 (pt) 2021-12-28
JP7587505B2 (ja) 2024-11-20
KR20220025698A (ko) 2022-03-03
MX2021008207A (es) 2021-11-04
EP3908664A1 (en) 2021-11-17
AU2026204884A1 (en) 2026-07-09
US20260193312A1 (en) 2026-07-09
SG11202107454UA (en) 2021-08-30
KR20260116815A (ko) 2026-07-28
IL284679A (en) 2021-08-31
KR102996287B1 (ko) 2026-07-24
CN113518823B (zh) 2025-05-02
WO2020146423A1 (en) 2020-07-16
AU2020207265A1 (en) 2021-08-12
US12497439B2 (en) 2025-12-16

Similar Documents

Publication Publication Date Title
US12497439B2 (en) Multi-functional fusion proteins and uses thereof
US20250115673A1 (en) Agonist fusion protein for cd40 and ox40 and uses thereof
JP7827324B2 (ja) インターロイキン－２バリアントおよびその使用方法
JP7148539B2 (ja) 免疫抱合体
Thompson et al. BAFF binds to the tumor necrosis factor receptor–like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population
JP4288159B2 (ja) 直列連鎖体を有する免疫接合体
US20220170028A1 (en) Novel interleukin-2 variants and bifunctional fusion molecules thereof
US7569663B2 (en) Chimeric proteins and methods for using the same
CN111587251B (zh) IgE Fc受体的α亚基的胞外域、包含其的药物组合物及其制备方法
KR20180131557A (ko) 면역요법에서의 tgf베타의 억제
KR20240005741A (ko) 특성이 향상된 이작용성 분자용 신규한 스캐폴드
CN113166253B (zh) 具有在CDR1区突变的人源化CD19 scFv的CAR-T细胞
KR20250051722A (ko) 멀티-도메인 결합 분자
US20220259281A1 (en) Chimeric protein expressing t-cells
US20250115657A1 (en) Bispecific FC Fusion Proteins with sPD-1 and IL-15
RU2815388C2 (ru) Многофункциональные слитые белки и их применения
US9920119B2 (en) Chimeric molecule involving oligomerized FasL extracellular domain
HK40060282A (en) Multi-functional fusion proteins and uses thereof
KR100418329B1 (ko) 직렬 연쇄체를 갖는 면역접합체
EP4382119A1 (en) A kit for use in the treatment of hematological cancer
HK1163129A (en) Cd86 antagonist multi-target binding proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)